Effects of Patient-Driven Lifestyle Modification Using Intermittently Scanned Continuous Glucose Monitoring in Patients With Type 2 Diabetes: Results From the Randomized Open-label PDF Study

被引:20
|
作者
Choe, Hun Jee [1 ,2 ]
Rhee, Eun-Jung [3 ]
Won, Jong Chul [4 ]
Park, Kyong Soo [1 ,2 ]
Lee, Won-Young [3 ]
Cho, Young Min [1 ,2 ]
机构
[1] Seoul Natl Univ, Dept Internal Med, Coll Med, Seoul, South Korea
[2] Seoul Natl Univ Hosp, Div Endocrinol & Metab, Dept Internal Med, Seoul, South Korea
[3] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Div Endocrinol & Metab, Dept Internal Med,Sch Med, Seoul, South Korea
[4] Inje Univ, Sanggye Paik Hosp, Div Endocrinol & Metab, Dept Internal Med, Seoul, South Korea
关键词
SENSING TECHNOLOGY; REAL-TIME; NUTRITION; RECOMMENDATIONS; MULTICENTER; MANAGEMENT; ADULTS; CARE;
D O I
10.2337/dc22-0764
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To investigate the effects of patient-driven lifestyle modification using intermittently scanned continuous glucose monitoring (isCGM) in patients with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS We conducted a 12-week, open-label, randomized controlled trial. A total of 126 participants were 1:1 randomized to either the intervention group (structured education + isCGM) or the control group (standard care with blood glucose monitoring). The Self-Evaluation Of Unhealthy foods by Looking at postprandial glucose (SEOUL) algorithm was developed and applied to aid structured education in guiding patients to follow healthy eating behavior depending on the postprandial glycemic response. The primary end point was the change in HbA(1c) level from baseline. RESULTS Implementation of the SEOUL algorithm with isCGM was associated with greater improvement in HbA(1c) than with standard care (risk-adjusted difference -0.50%, 95% CI -0.74 to -0.26, P < 0.001). Participants in the intervention group had a greater reduction in fasting blood glucose and body weight (-16.5 mg/dL, 95% CI -30.0 to -3.0, P = 0.017; -1.5 kg, 95% CI -2.7 to -0.3, P = 0.013, respectively). The score sum for the Korean version of the revised Summary of Diabetes Self-Care Activities Questionnaire increased in both groups but to a greater extent in the intervention group (mean difference 4.8, 95% CI 1.7-8.0, P = 0.003). No severe hyperglycemia or hypoglycemia was reported in either group of patients. CONCLUSIONS Patient-driven lifestyle modification primarily focused on eating behavior using isCGM effectively lowered HbA(1c) levels in patients with T2D.
引用
收藏
页码:2224 / 2230
页数:7
相关论文
共 50 条
  • [21] Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial
    Takashima, Hiroyuki
    Yoshida, Yoshinori
    Nagura, Chinami
    Furukawa, Tetsuya
    Tei, Ritsukou
    Maruyama, Takashi
    Maruyama, Noriaki
    Abe, Masanori
    DIABETES & VASCULAR DISEASE RESEARCH, 2018, 15 (05): : 469 - 472
  • [22] Effects of linagliptin vs. voglibose on daily glucose excursions during continuous glucose monitoring of Japanese type 2 diabetes patients (L-CGM): A randomized, open-label, two-arm, parallel comparative trial
    Satoh, H.
    Ohira, T.
    Moriya, C.
    Inoue, I.
    Kuribayashi, S.
    Seino, H.
    Hirai, H.
    Hiyoshi, T.
    Watada, H.
    DIABETES & METABOLISM, 2017, 43 (06) : 550 - 553
  • [23] Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study
    Schmidt, W. E.
    Christiansen, J. S.
    Hammer, M.
    Zychma, M. J.
    Buse, J. B.
    DIABETIC MEDICINE, 2011, 28 (06) : 715 - 723
  • [24] Clinical efficacy of Professional Continuous Glucose Monitoring in improving glycemic control among children with Type 1 Diabetes Mellitus: An Open-label Randomized Control Trial
    Raviteja, K., V
    Kumar, Rakesh
    Dayal, Devi
    Sachdeva, Naresh
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [25] Clinical efficacy of Professional Continuous Glucose Monitoring in improving glycemic control among children with Type 1 Diabetes Mellitus: An Open-label Randomized Control Trial
    K. V. Raviteja
    Rakesh Kumar
    Devi Dayal
    Naresh Sachdeva
    Scientific Reports, 9
  • [26] Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study
    Jaiswal, Mamta
    Martin, Catherine L.
    Brown, Morton B.
    Callaghan, Brian
    Albers, James W.
    Feldman, Eva L.
    Pop-Busui, Rodica
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2015, 29 (08) : 1287 - 1294
  • [27] Assessment of factors associated with improved glycemic control after switching from intermittently scanned to real-time continuous glucose monitoring in Japanese patients with type 1 diabetes
    Yamada, Eijiro
    Nakajima, Yasuyo
    Horiguchi, Kazuhiko
    Okada, Shuichi
    Yamada, Masanobu
    ENDOCRINE JOURNAL, 2023, 70 (12) : 1187 - 1193
  • [28] Randomized Study Comparing Continuous Glucose Monitoring and Capillary Glucose Testing in Patients With Type 2 Diabetes After Hospital Discharge
    Umpierrez, Guillermo E.
    Castro-Revoredo, Iris
    Moazzami, Bobak
    Nayberg, Irina
    Zabala, Zohyra
    Galindo, Rodolfo J.
    Vellanki, Priyathama
    Peng, Limin
    Klonoff, David C.
    ENDOCRINE PRACTICE, 2025, 31 (03) : 286 - 291
  • [29] Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial
    Petkovic-Dabic, Jelena
    Binic, Ivana
    Caric, Bojana
    Bozic, Ljiljana
    Umicevic-Sipka, Sanja
    Bednarcuk, Natasa
    Dabic, Sasa
    Situm, Mirna
    Popovic-Pejicic, Snjezana
    Stojiljkovic, Milos P.
    Skrbic, Ranko
    BIOMOLECULES, 2025, 15 (01)
  • [30] CGM-BASED CLINICAL TARGETS IN ADULTS WITH TYPE1 AND TYPE2 DIABETES USING INTERMITTENTLY SCANNED CONTINUOUS GLUCOSE MONITORING (FREESTYLE LIBRE SYSTEM): AN ITALIAN EXPERIENCE
    Morpurgo, P.
    Rossi, A.
    Lunati, M. E.
    Chebat, E.
    Gandolfi, A.
    Laneri, M.
    Fiorina, P.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 : A135 - A136